Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
about
Cancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentEpigenetic treatment of solid tumours: a review of clinical trialsEpigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Class I HDAC imaging using [ (3)H]CI-994 autoradiographyThree-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.Interpreting clinical assays for histone deacetylase inhibitors.Systemic therapy for metastatic pancreatic adenocarcinoma.Preclinical models of pancreatic ductal adenocarcinoma.Enhancement of human sodium iodide symporter gene therapy for breast cancer by HDAC inhibitor mediated transcriptional modulation.Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics.Histone deacetylase inhibitors and pancreatic cancer: are there any promising clinical trials?Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.Histone deacetylase inhibitors in lymphoma and solid malignancies.Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.Targeting histone deacetylases for the treatment of diseaseTargeting histone deacetylases in pancreatic ductal adenocarcinoma.A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.Treatment options for advanced pancreatic cancer: a review.Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials.Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.Thymoquinone Promotes Pancreatic Cancer Cell Death and Reduction of Tumor Size through Combined Inhibition of Histone Deacetylation and Induction of Histone Acetylation.BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.Use of a genome-wide haploid genetic screen to identify treatment predicting factors: a proof-of-principle study in pancreatic cancer.Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma.Histone deacetylase inhibitors in cancer therapy
P2860
Q26740619-B6FF6239-79FC-47F2-B13F-9DEE351F5AD3Q26773803-08BC564E-7DE2-485B-B63E-9BB90EE6B3B7Q28076548-BC0DBFF8-081B-49D2-A633-B5645FFA35F7Q28533258-AF1E6845-3F6B-42A7-A07B-A028CD20DCC1Q33403498-DFDFF5AC-5CD4-4D10-91D9-BD3E2ED3B6EBQ33842416-982144B8-D97C-4CB8-B06B-0337025F0B5EQ33844751-60A31F17-A117-4262-939E-3B34E418C7F7Q34353711-FBFFE311-4C1C-48C1-A54E-812D9564E63CQ34734222-028D65BD-0ACA-442A-9B89-565D95FFD31EQ34818494-FB28E0DC-F621-4F8B-B72E-455DE23FE788Q35003657-56BB11A5-C2D3-4066-B797-C6630E1C7B46Q35076238-D51BBE32-550A-432B-90EC-27DFD6CCF138Q36428208-B32D7161-EC94-4BAB-83EB-2B02ADD32B38Q36499907-0060A295-2713-4D3F-BC64-F9F637D237F3Q36537788-5639D753-E77E-412B-8760-A6A3BAC3A9B7Q36654454-7ECD89B7-7CE0-4A18-956B-A363C3BE5BCDQ36654923-BF1564C5-74A0-4C52-9FA1-B2D7A3DE414CQ37013055-A2C070D6-6AC7-461F-BFD5-C298A3BE3266Q37118947-7BC746A6-ED97-47C7-A66D-C91B627087A6Q37284812-A15CDB45-E4DE-4456-B894-29ABD7D1ABF8Q37296159-D0122BC1-C668-4581-916A-1C5661CB6904Q37310587-084CE8A6-B384-4798-8842-AB22CDA58B1AQ37612692-D1BBC7CD-87D0-4AEB-9005-126470841129Q37994505-68F9BDB9-3911-43C1-9694-1EF75A0D4FD7Q38012499-2872F8EE-6D20-48CC-A1A3-75C9F6EAFAEAQ38062020-D703909B-69EC-4560-907A-57FEC34895CBQ38081988-F6E5F804-B27B-4F10-8653-87057924DE6EQ39204274-8704C97C-5CE5-479E-BA9D-8FAB61F95585Q40973109-1B678945-26CB-44C4-B9C6-49AFDE0ABACCQ42128109-5CE7815C-2AE7-48D7-B02B-E5214E57A6CFQ42362715-ADC89E44-BA23-42D7-BA63-47164FA74667Q49853764-16470AFF-7EDD-4D48-9E02-07A8EDF2E13DQ53768454-9C05694A-DB2F-421D-BBDC-F8ACEBB1130AQ57272462-ACE39360-E9D9-4A5D-83EC-32AAF5F8F4C0
P2860
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Gemcitabine plus CI-994 offers ...... controlled, multicenter study.
@ast
Gemcitabine plus CI-994 offers ...... controlled, multicenter study.
@en
type
label
Gemcitabine plus CI-994 offers ...... controlled, multicenter study.
@ast
Gemcitabine plus CI-994 offers ...... controlled, multicenter study.
@en
prefLabel
Gemcitabine plus CI-994 offers ...... controlled, multicenter study.
@ast
Gemcitabine plus CI-994 offers ...... controlled, multicenter study.
@en
P2093
P2860
P356
P1433
P1476
Gemcitabine plus CI-994 offers ...... controlled, multicenter study.
@en
P2093
A Rosemurgy
D A Richards
D J Wagener
D M Waterhouse
K Macdonald
S S Krishnamurthi
P2860
P304
P356
10.1093/ANNONC/MDL081
P577
2006-04-26T00:00:00Z